Compared with mock-treated cells, alirocumab treatment restored plasma membrane levels of LDLR in DENV-infected cells (Figure 2E) and resulted in lower DENV plaque titers 24 and 48 hours post infection (hpi) (Figure 2, F and G). Here, LDLR is linked to infection.